Compare Atmos Energy Corporation (ATO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Atmos Energy Corporation trades at $178.45 (market cap $29.79B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Atmos Energy Corporation is far larger — about 310.8× Inovio Pharmaceuticals Inc's market cap, and Atmos Energy Corporation pays a 2.24% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ATO | INO | |
|---|---|---|
Market Cap | $29.79B | $95.85M |
Sector | Utilities | Health |
52-Week High | $192.25 | $2.87 |
52-Week Low | $154.10 | $1.05 |
Enterprise Value | $39.29B | $66.86M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $179.50, up 1.87% on the day, with a bullish technical outlook and strong support near $179. The stock shows solid fundamentals with a P/E of 22.11, revenue of $4.70B in 2025, and net income margin of 27.58%. Recent news highlights its position to benefit from data center demand and regulatory support, with an upcoming Q3 earnings call on August 6, 2026.
The outlook is positive with a consensus price target of $191.00, though risks include high capital expenditures and debt levels. Earnings growth and dividend stability provide upside, but investors should monitor execution on capex plans and interest rate impacts.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
